European Leukemia Trial Registry
Trial: AMLSG 05-04

More Details
Scientific Title Phase II Study on Gemtuzumab Ozogamicin in Combination With All-Trans-Retinoic Acid, High-Dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia
Short Title AMLSG 05-04
Trialgroup AMLSG Ulm
Type of Trial multicentric
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age <= 60 years
Status Closed
Start of Recruitment 11.05.2004
Leader Schlenk, Prof. Dr. med., Richard
Contactperson

General Contact Person
Schlenk, Prof. Dr. med., Richard
Tel: +49 (0)731 500-45900
Fax: +49 (0)731 500-45905
Email: richard.schlenk@uniklinik-ulm.de

Biometrics
Benner, A.
Tel: +49 (0)6221 422390
Fax: +49 (0)6221 422397
Email: benner@dkfz-heidelber.de
Homepage: www.dkfz.de

Centre of Trial Universitätsklinikum Ulm
Shortprotocol Shortprotocol
Diagnostics

Cytogenetics
Labor für Zytogenetische und Molekulargenetische Diagnostik, Klinik für Innere Med. III, Universitätsklinikum Ulm

Immunophaenotyping
Immunphänotypisierung, Med.Klinik III, Universität Ulm

Molecular biology
Institut für Humangenetik, Medizinische Hochschule Hannover (MHH)

created 04.07.2006 Anja Hellenbrecht
changed 24.07.2017 Eva-Maria Ableidinger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org